NCT01950468View on ClinicalTrials.gov

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2017

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Parkinson's Syndrome
Interventions
DRUG

NAV5001

A single intravenous dose of 8.0 ± 1.0 mCi

DRUG

DaTscan

A single intravenous dose of 3 to 5 mCi

Trial Locations (2)

32806

Compass Research, Orlando

85004

Xenoscience, Inc., Phoenix

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY